Onderzoeksoutput per jaar
Onderzoeksoutput per jaar
Onderzoeksoutput
- 17 resultaten
Zoekresultaten
-
2022
Assessment of repeatability and uptake quantification of (68)GaNOTA-anti-HER2 sdAb PET/CT in patients with locally advanced or metastatic breast cancer
Gondry, O., Xavier, C., Waelput, W., Al Dabssi, O., Vanhoeij, M., Aspeslagh, S., Joris, S., Fontaine, C., Verfaillie, G., De Greve, J., Glorieus, K., Luyten, I., Vandenbroucke, F., Bourgeois, S., Thyparambil, S., Devoogdt, N., Vaneycken, I., Cousaert, J., Caveliers, V., Everaert, H. & 3 anderen, , 15 feb 2022, In: Cancer Research. 82, 4, blz. P3-02-05Onderzoeksoutput: Meeting abstract (Journal)
Open Access -
2021
Assessment of sacituzumab govitecan (SG) in patients with prior neoadjuvant/adjuvant chemotherapy in the phase 3 ASCENT study in metastatic triple-negative breast cancer (mTNBC).
Carey, L. A., Loirat, D., Punie, K., Bardia, A., Dieras, V., Dalenc, F., Diamond, J. R., Fontaine, C., Wang, G., Rugo, H. S., Hurvitz, S. A., Kalinsky, K., O'Shaughnessy, J., Loibl, S., Gianni, L., Piccart-Gebhart, M. J., Hong, Q., Olivo, M. S., Itri, L. & Cortes, J., 20 mei 2021, In: Journal of Clinical Oncology. 39, 15, blz. 1080-1080Onderzoeksoutput: Meeting abstract (Journal)
Open Access -
2020
Evaluation of germline whole exome sequencing of early breast cancer patients with triple negative breast cancer (TNBC) included in a prospective study of neoadjuvant chemotherapy (NAC) with epirubicin and cyclophosphamide (EC) and carboplatin-paclitaxel (PC) (BSMO 2014-01)
Fontaine, C., Renard, V., Van den Bulck, H., Vuylsteke, P., Glorieux, P., Dopchie, C., Decoster, L., Awada, A., Wildiers, H., De Brakeleer, S., Teugels, E. & De Greve, J., feb 2020, In: Cancer Research. 80, 4, P1-10-05.Onderzoeksoutput: Meeting abstract (Journal)
Open Access -
Quality of life in survivors of stage I-II breast cancer, 10 years outcome of a randomized clinical trial comparing post-operative hypofractionation with Tomotherapy versus conventional radiation treatment (TomoBreast)
Van Parijs, H., Vinh-Hung, V., Fontaine, C., Storme, G. A., Adriaenssens, N., Hanon, S., Vanhoeij, M., Lustberg, M. B., Williams, N., Nguyen, D. M., Nguyen, N. P., Verschraegen, C. & De Ridder, M., feb 2020, In: Cancer Research. 80, 4, P2-13-01.Onderzoeksoutput: Meeting abstract (Journal)
Open Access -
Quality of life in survivors of stage I-II breast cancer. 10 years outcome of a randomized clinical trial comparing post-operative hypofractionation with Tomotherapy versus conventional radiation treatment (TomoBreast)
Van Parijs, H., Vinh - Hung, V., Fontaine, C., Storme, G., Hanon, S., Vanhoeij, M., Lustberg, M., Williams, N., Nguyen, D., Nguyen, D. N., Verschraegen, C. & De Ridder, M., feb 2020, In: Cancer Research. 80Onderzoeksoutput: Meeting abstract (Journal)
-
2019
Poster presentation. Phase II trial of HER2-PET/CT using 68Ga-anti-HER2 VHH1 for characterization of HER2 presence in brain metastases of breast cancer patients
Keyaerts, M., Xavier, C., Everaert, H., Vaneycken, I., Fontaine, C., Decoster, L., Vanhoeij, M., Caveliers, V. & Lahoutte, T., 1 mei 2019, In: Annals of Oncology. 30, (suppl_3): iii1-iii26. 10.1093/annonc/mdz095, 85TiP.Onderzoeksoutput: Meeting abstract (Journal)
-
2018
Final results of weekly (w) neoadjuvant carboplatin (Cp) added to paclitaxel (P) followed by epirubicin (E) and cyclophosphamide (C) in triple negative breast cancer (TNBC) patients (pts): A BSMO breast cancer task force phase II study
Fontaine, C., Cappoen, N., Renard, V., Van den Bulck, H., Vuylsteke, P., Glorieux, P., Dopchie, C., Decoster, L., De Greve, J., Awada, A. & Wildiers, H., feb 2018, In: Cancer Research. 78, 4Onderzoeksoutput: Meeting abstract (Journal)
Open Access -
Phase I results of CAM-H2: Safety profile and tumor targeting in patients.
Keyaerts, M., De Vos, J., Duhoux, F. P., Caveliers, V., Fontaine, C. & Vanhoeij, M., 20 mei 2018, In: Journal of Clinical Oncology. 36, 15, blz. e13017-e13017 1 blz.Onderzoeksoutput: Meeting abstract (Journal)
-
2017
Neoadjuvant weekly carboplatin and paclitaxel followed by dose dense epirubicin and cyclophosphamide in triple negative breast cancer patients
Fontaine, C., Cappoen, N., Renard, V., Vuylsteke, P., Van den Bulck, H., Glorieux, P., de Roodenbeke, D. TK., Dopchie, C., Decoster, L., Vanacker, L., De Greve, J., Awada, A. & Wildiers, H., feb 2017, In: Cancer Research. 77, 4Onderzoeksoutput: Meeting abstract (Journal)
-
Updated results of the Breast cancer task force phase II study of neoadjuvant weekly carboplatin (Cp) added to paclitaxel (P) followed by epirubicin (E) and cyclophosphamide (C) in triple negative breast cancer (TNBC) patients (pts)
Fontaine, C., Cappoen, N., Renard, V., Van Den Bulk, H., Vuylsteke, P., Glorieux, P., Decoster, L., Vanhoeij, M., De Greve, J., Awada, A. & Wildiers, H., sep 2017, In: Annals of Oncology. 28, 168P, blz. 168POnderzoeksoutput: Meeting abstract (Journal)
-
2016
Adjuvant chemotherapy with 3-weekly cyclophosphamide and dose dense paclitaxel in early breast cancer patients older than 65 years, a retrospective study
Fontaine, C., Joris, S., Decoster, L., Vanacker, L., Schallier, D., Vanhoeij, M., Verfaillie, G., Lamote, J. & De Greve, J., apr 2016, In: European Journal of Cancer. 57, blz. S102-S103 2 blz.Onderzoeksoutput: Meeting abstract (Journal)
53 Citaten (Scopus) -
Health-related quality of life in breast cancer patients prior to and 3 years following adjuvant radiotherapy: Comparison between conventional and short-course, image-guided radiotherapy.
Adriaenssens, N., De Ridder, M., Lamote, J., Fontaine, C., Van Parijs, H., Storme, G., Versmessen, H., Miedema, G., De Greve, J. & Vinh-Hung, V., 20 jan 2016, In: Journal of Clinical Oncology. 34, s3, 1 blz., 247.Onderzoeksoutput: Meeting abstract (Journal)
-
The influence of multidisciplinary rehabilitation on physical well-being and quality of life of breast cancer survivors
Adriaenssens, N., Fontaine, C., Vanhoeij, M., Lamote, J. & De Greve, J., 20 jan 2016, In: Journal of Clinical Oncology. 34, 3s, 1 blz., 143.Onderzoeksoutput: Meeting abstract (Journal)
-
2015
Nanobody-based PET/CT imaging of HER2 expression in breast carcinoma: Phase I results and potential to assess tumor heterogeneity.
Keyaerts, M., Xavier, C., Heemskerk, J., Devoogdt, N., Everaert, H., Gevaert, T., Vanhoeij, M., Duhoux, F. P., Simon, P., Schallier, D. C. C., Fontaine, C., Vaneycken, I., Vanhove, C., De Greve, J., Lamote, J., Caveliers, V. & Lahoutte, T., 20 mei 2015, In: Journal of Clinical Oncology. 33, 15, blz. Suppl S 1 blz., e11600.Onderzoeksoutput: Meeting abstract (Journal)
Open Access -
Prospective study of aromatase inhibitor-induced bone loss and lipid levels in early hormone sensitive breast cancer treated with AI during 8 years
Fontaine, C., Decoster, L., Schallier, D., Vanacker, L., De Greve, J., Vanhoeij, M., Verfaillie, G. & Lamote, J., 1 mei 2015, In: Cancer Research. 75, 9, 1 blz.Onderzoeksoutput: Meeting abstract (Journal)
-
2010
Tyrosine kinase inhibitor (tki)-induced macrocytosis
Schallier, D., Trullemans, F., Fontaine, C., Decoster, L. & De Greve, J., 2010, In: Acta Clinica Belgica. 65, March-April, blz. 156-156 1 blz.Onderzoeksoutput: Meeting abstract (Journal)
-
2009
Short Term Evaluation of a Comprehensive Post Treatment Rehabilitation Program for Cancer Patients Treated with Curative Intent
Hanssens, S., Luyten, R., Blanken, W., Watthy, C., Fontaine, C., Decoster, L., Baillon, C., Trullemans, F. & De Greve, J., 2009, In: Cancer Research. 69, December, 1 blz.Onderzoeksoutput: Meeting abstract (Journal)